目的 探究双氢青蒿素(dihydroartemisinin, DHA)联合吉非替尼(gefitinib, GEF)对肺腺癌细胞系的细胞周期和迁移能力的影响。方法 10 μM DHA和(或)50 μM GEF处理肺腺癌细胞系A549和SPC-A-1,四唑盐(methyl thiazolyl tetrazolim, MTT)比色法检测细胞增殖,流式细胞术检测细胞周期,划痕实验检测细胞迁移,蛋白质印记法(western blot, WB)检测单独或联合应用DHA和GEF对细胞周期和迁移相关蛋白表达的影响。结果 MTT实验结果显示联合应用DHA和GEF(Com组)后,A549和SPC-A-1的增殖能力显著低于单药组和对照(NC)组,且具有时间依赖性(P＜0.05);碘化丙啶(propidium iodide, PI)单染流式细胞术检测细胞阻滞于G0/G1期;WB显示与NC组和单药组相比,Com组细胞周期蛋白依赖性蛋白激酶4(cyclin dependent kinase 4,CDK4)和细胞周期素D1(Cyclin D1)表达显著下降;划痕实验中Com组细胞融合率显著低于NC组和单药组,并伴随基质金属蛋白酶(matrix metalloproteinase, MMP)2和MMP9表达下降,差异均具有统计学意义(P＜0.05)。结论 DHA联合GEF可以显著抑制肺腺癌细胞的增殖和迁移,并阻滞细胞周期。
Abstract
Objective To explore the combined effect of dihydroartemisinin (DHA) and gefitinib (GEF) in lung adenocarcinoma cell lines.Methods Lung adenocarcinoma cell lines A549 and SPC-A-1 were treated with 10μM DHA and (or) 50μM GEF. MTT assay was used to detect cell proliferation, while flow cytometry was adopted to determine cell cycle. Cell migration was observed with cell scratch tests. The effects of DHA and GEF alone or in combination on the expressions of proteins related to cycle and migration were detected by Western blot.Results MTT results showed that DHA combined with GEF(Com group) inhibited the proliferation of A549 and SPC-A-1 cell lines more significantly than in control and single drug groups and in a time-dependent manner (P<0.05). Flow cytometry with PI staining showed that cell cycles were blocked at G0/G1 phase. Western blot showed that the expressions of CDK4 and Cyclin D1 in the Com group decreased more significantly than in control and single drug groups. Cell fusion rate of Com group was also significantly lower than that of control and single drug groups in cell scratch test and the expressions of MMP2 and MMP9 were decreased. The difference was statistically significant (P<0.05).Conclusions DHA combined with GEF can significantly inhibit the proliferation and migration of lung adenocarcinoma cells and block cell cycle.
关键词
双氢青蒿素 /
吉非替尼 /
肺腺癌 /
周期 /
迁移
Key words
dihydroartemisinin /
Gefitinib /
lung adenocarcinoma /
cell cycle /
migration
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Ernani V, Steuer C E,Jahanzeb M. The end of nihilism: systemic therapy of advanced non-small cell lung cancer[J]. Annu Rev Med, 2017, 68(1): 153-168.
[3] Vijayvergia N,Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer[J]. Cancer Chemother Pharmacol, 2014, 74(3): 437-446.
[4] Giannoni E, Bianchini F, Masieri L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness[J]. Cancer Res, 2010, 70(17): 6945-6956.
[5] Neri S, Ishii G, Hashimoto H, et al. Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma[J]. Int J Cancer, 2015, 137(4): 784-796.
[6] 袁 钢,韩 涛,刘中正,等. 厄罗替尼治疗晚期非小细胞肺癌临床疗效[J].临床军医杂志, 2018, 46(3): 298-301.
[7] Cataldo V D, Gibbons D L, Perez-Soler R, et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib[J]. N Engl J Med, 2011, 364(10): 947-955.
[8] Shi Y, Au J S, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014, 9(2): 154-162.
[9] Maemondo M,Inoue A,Kobayashi K,et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med,2010, 362(25): 2380-2388.
[10] Li Y, Sui H, Jiang C, et al. Dihydroartemisinin increases the sensitivity of photodynamic therapy via NF-kappaB/HIF-1alpha/VEGF pathway in esophageal cancer cell in vitro and in vivo[J]. Cell Physiol Biochem, 2018, 48(5): 2035-2045.
[11] Chen H, Gu S, Dai H, et al. Dihydroartemisinin sensitizes human lung adenocarcinoma A549 cells to arsenic trioxide via apoptosis[J]. Biol Trace Elem Res, 2017, 179(2): 203-212.
[12] Diluvio G, Del Gaudio F, Giuli M V, et al. NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest[J]. Oncogenesis, 2018, 7(5): 42.
[13] Peng M, Huang Y, Tao T, et al. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk[J]. Sci Rep, 2016, 6: 28611.
[14] 冯 佳,彭 敏,胡伟国,等. 非小细胞肺癌对酪氨酸激酶抑制剂获得性耐药机制及治疗策略的研究进展[J]. 中国肿瘤学杂志,2017,23(1):6-12.
[15] 彭 晖. EGFR突变的非小细胞肺癌耐药机制及其克服新策略[J]. 国际药学研究杂志,2011, 38(2): 96-104.
[16] Wong Y K, Xu C, Kalesh K A, et al. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action[J]. Med Res Rev, 2017, 37(6): 1492-1517.
[17] Shao Y Y, Zhang T L, Wu L X, et al. AKT Axis, miR-21, and RECK play pivotal roles in dihydroartemisinin killing malignant glioma cells[J]. Int J Mol Sci, 2017, 18(2): 350.
[18] Hu Y J, Zhang J Y, Luo Q, et al. Nanostructured dihydroartemisinin plus epirubicin liposomes enhance treatment efficacy of breast cancer by inducing autophagy and apoptosis[J]. Nanomaterials (Basel), 2018, 8(10): 804.
[19] Gu C D, Osaki T, Oyama T, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and survival[J]. Ann Surg, 2002, 235(1): 133-139.
[20] Martins V L, Caley M,O’Toole E A. Matrix metalloproteinases and epidermal wound repair[J]. Cell Tissue Res, 2013, 351(2): 255-268.
PDF(1024 KB)
